HUTCHMED (HCM) News Today $16.11 +0.78 (+5.08%) Closing price 03:59 PM EasternExtended Trading$16.11 +0.01 (+0.04%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period HUTCHMED (NASDAQ:HCM) Shares Gap Up - Should You Buy?HUTCHMED (NASDAQ:HCM) Shares Gap Up - Here's WhyFebruary 20 at 11:53 AM | marketbeat.comHUTCHMED to Announce 2024 Final ResultsFebruary 19 at 3:30 AM | globenewswire.comABC Arbitrage SA Makes New $500,000 Investment in HUTCHMED (China) Limited (NASDAQ:HCM)ABC Arbitrage SA acquired a new position in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 34,710 shares of the company's stock, valued at approximately $500,000. A number of other insFebruary 16, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Reaches New 52-Week Low - Should You Sell?HUTCHMED (NASDAQ:HCM) Hits New 1-Year Low - Here's What HappenedFebruary 12, 2025 | marketbeat.comBank of America Securities Remains a Buy on HUTCHMED (HCM)February 11, 2025 | markets.businessinsider.comHutchmed price target raised to $27 from $26 at BofAFebruary 11, 2025 | markets.businessinsider.com46,676 Shares in HUTCHMED (China) Limited (NASDAQ:HCM) Acquired by XY Capital LtdXY Capital Ltd bought a new position in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 46,676 shares of the company's stock, valued at approxiFebruary 10, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Down - Time to Sell?HUTCHMED (NASDAQ:HCM) Shares Gap Down - Time to Sell?February 7, 2025 | marketbeat.comHUTCHMED (China) Limited (NASDAQ:HCM) Short Interest Down 12.5% in JanuaryHUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 412,700 shares, a drop of 12.5% from the December 31st total of 471,700 shares. Based on an average daily volume of 78,100 shares, the days-to-cover ratio is presently 5.3 days.February 1, 2025 | marketbeat.comDespite A Promising Future For Hutchmed, We Have Concerns About Development Of The Share Price (Rating Downgrade)January 30, 2025 | seekingalpha.comHUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's What HappenedHUTCHMED (NASDAQ:HCM) Shares Gap Down - Time to Sell?January 23, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - What's Next?HUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy?January 17, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading Volume - Here's What HappenedHUTCHMED (NASDAQ:HCM) Sees Strong Trading Volume - Here's WhyJanuary 16, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Down - Should You Sell?HUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's WhyJanuary 15, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Stock Price Passes Below 50 Day Moving Average - What's Next?HUTCHMED (NASDAQ:HCM) Share Price Crosses Below 50 Day Moving Average - Here's What HappenedJanuary 15, 2025 | marketbeat.comHutchmed announces NMPA approval for Orpathys supplemental new drug applicationJanuary 14, 2025 | markets.businessinsider.comHUTCHMED’s ORPATHYS® Receives Full NMPA Approval for Expanded NSCLC TreatmentJanuary 13, 2025 | tipranks.comHUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLCJanuary 13, 2025 | globenewswire.comHUTCHMED (NASDAQ:HCM) Trading Down 4.5% - Should You Sell?HUTCHMED (NASDAQ:HCM) Stock Price Down 4.5% - Here's WhyJanuary 7, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Sees Strong Trading Volume - Still a Buy?HUTCHMED (NASDAQ:HCM) Sees Strong Trading Volume - Still a Buy?January 6, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - Here's What HappenedHUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy?January 2, 2025 | marketbeat.comChinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 MillionJanuary 2, 2025 | benzinga.comHUTCHMED's Combination Therapy For Lung Cancer Granted Priority Review By NMPAJanuary 1, 2025 | markets.businessinsider.comHUTCHMED’s Lung Cancer Drug Combo Gains Priority ReviewJanuary 1, 2025 | tipranks.comHUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor TherapyJanuary 1, 2025 | globenewswire.comBillionaire Li Ka-shing's Hutchmed in $608 mln health unit stake salesJanuary 1, 2025 | reuters.comHUTCHMED (China) Limited (NASDAQ:HCM) Sees Significant Decline in Short InterestHUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) was the recipient of a significant drop in short interest in December. As of December 15th, there was short interest totalling 467,900 shares, a drop of 8.1% from the November 30th total of 509,300 shares. Based on an average daily volume of 95,100 shares, the days-to-cover ratio is presently 4.9 days.January 1, 2025 | marketbeat.comHUTCHMED Sells Major Stake to Focus on Core BusinessJanuary 1, 2025 | tipranks.comHUTCHMED Announces US$608 million Divestment of Non-Core Joint VentureJanuary 1, 2025 | globenewswire.comHUTCHMED Expands Brokerage Partnerships in LondonDecember 31, 2024 | tipranks.comHUTCHMED’s Share Option Scheme Update and Stock IssuanceDecember 30, 2024 | tipranks.comJane Street Group LLC Raises Stock Holdings in HUTCHMED (China) Limited (NASDAQ:HCM)Jane Street Group LLC lifted its stake in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 362.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 62,997 shares of the company's stock afterDecember 29, 2024 | marketbeat.comPaycor HCM: Positive On The Mid-Term Growth Outlook (Rating Upgrade)December 25, 2024 | seekingalpha.comHUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's WhyHUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's What HappenedDecember 16, 2024 | marketbeat.comHutchmed announces BTD in China for Orpathys, Tagrisso combinationDecember 12, 2024 | markets.businessinsider.comHUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)December 12, 2024 | finance.yahoo.comHUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)December 12, 2024 | globenewswire.comHUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor TherapyDecember 11, 2024 | globenewswire.comBNP Paribas Financial Markets Sells 132,711 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)BNP Paribas Financial Markets trimmed its position in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 69.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 58,443 shares of the company's stock after sellDecember 10, 2024 | marketbeat.comInnovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial CancerDecember 3, 2024 | prnewswire.comHUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial CancerDecember 3, 2024 | globenewswire.comHUTCHMED (China) Limited (NASDAQ:HCM) Stake Cut by Bellevue Group AGBellevue Group AG decreased its holdings in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 97.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,015 shares of the company's stock afterDecember 2, 2024 | marketbeat.comHUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current TermsNovember 28, 2024 | markets.businessinsider.comHUTCHMED Announces Renewal Of ORPATHYS Inclusion In China's NRDLNovember 28, 2024 | markets.businessinsider.comHUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current TermsNovember 28, 2024 | globenewswire.comHutchmed to receive milestone payment following Takeda launch of FruzaqlaNovember 22, 2024 | msn.comHUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in JapanNovember 21, 2024 | globenewswire.comHUTCHMED (China) (NASDAQ:HCM) Stock, Option ChainNovember 21, 2024 | benzinga.comHUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board CommitteeNovember 20, 2024 | globenewswire.comHUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by M&G PlcM&G Plc raised its holdings in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 98.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 267,231 shares of the company's stock after acquiring an additional 132,333 shares during the quarterNovember 9, 2024 | marketbeat.com Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address HCM Media Mentions By Week HCM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HCM News Sentiment▼0.910.60▲Average Medical News Sentiment HCM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HCM Articles This Week▼32▲HCM Articles Average Week Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies QGEN News ASND News ROIV News RVMD News LEGN News BBIO News AXSM News BPMC News TLX News ELAN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HCM) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share HUTCHMED With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HCM Stock Alerts